Evidence map›Paper›PMID 41661462›Full record

ReviewDiscover oncology2026

The role of deubiquitinase USP33 in colorectal cancer tumorigenesis and its potential as a therapeutic target predictor.

Yu Dai, Xinyu Luo, Heng Wu, Yajun Luo, Zijian Deng, Jiqiang Wu, Li Zhang, Jin Yan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yu Dai *Department of Oncology, The Affiliated Hospital of Southwest Medical University, Street Taiping No.25, region, Jiangyang, Luzhou, 646099, Sichuan, China.
Xinyu Luo *Department of Oncology, The Affiliated Hospital of Southwest Medical University, Street Taiping No.25, region, Jiangyang, Luzhou, 646099, Sichuan, China.
Heng Wu *Department of Spine Surgery, The Affiliated Hospital of Chengdu Sport University, Chengdu, 610041, China.
Yajun LuoSchool of Medicine, Sichuan Cancer Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Zijian DengSchool of Medicine, Sichuan Cancer Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Jiqiang WuDepartment of Rheumatology and Immunology, The Affiliated Hospital of Southwest Medical University, Street Taiping No.25, Region Jiangyang, Luzhou, 646099, Sichuan, China.
Li ZhangSchool of Medicine, Sichuan Cancer Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, China. zhangli@scszlyy.org.cn.
Jin YanDepartment of Oncology, The Affiliated Hospital of Southwest Medical University, Street Taiping No.25, region, Jiangyang, Luzhou, 646099, Sichuan, China. yanjin_1111@163.com.

Funding

the National Natural Science Fund of China No. 82302993the Youth of Sichuan Science and Technology Program No. 2023NSFSC1896
6 · The paper itself

Abstract

Deubiquitination(DUB) is a critical cellular process that regulates protein stability and functionality, playing essential roles in cell proliferation, migration, tumorigenesis, and various molecular signaling pathways. Within the DUB enzyme family, ubiquitin-specific protease 33 (USP33) is found to be aberrantly expressed in several cancers, including a significant reduction in colorectal cancer (CRC) tissues. The decreased expression of USP33 impairs its ability to inhibit CRC cell proliferation, migration, and invasion, potentially through its involvement in key signaling pathways such as the β-arrestin-dependent ERK pathway, Slit-Robo pathway, and Wnt/β-catenin pathway. This review highlights the interaction between USP33 and these signaling pathways, exploring its potential as a novel independent prognostic biomarker for CRC and its promise as a therapeutic target.

Indexed as

Colorectal cancerSlit-RoboUSP33Wnt/β-cateninΒ-arrestin-dependent ERK

Identifiers

PMID41661462
PMCPMC12988078

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.